Skip to main content
SpringerLink
Log in

Psychopharmacologic Management of Eating Disorders

  • Eating Disorders (J Steinglass, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Identifying medications that may be used as therapeutic agents for eating disorders is a longstanding focus of research, with varying degrees of success. The present review consolidates the most recent findings on pharmacological treatment of three eating disorders, including anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED).

Recent Findings

Recent research suggests that olanzapine demonstrates positive effects on weight gain among outpatients with AN. There are fewer recent advances in psychopharmacological treatment for BN and BED, likely due to the relative success of prior medication trials.

Summary

Olanzapine is the first medication to safely promote weight gain among individuals with AN. Fluoxetine is FDA-approved for BN treatment, and lisdexamfetamine is FDA-approved for BED treatment. BN and BED also generally respond well to SSRIs prescribed off-label. Research on psychopharmacological treatments for other eating disorders, such as avoidant-restrictive food intake disorder and other specified feeding and eating disorders, are sorely needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. Washington, DC; 2013.

  2. Ágh T, Kovács G, Supina D, Pawaskar M, Herman BK, Vokó Z, et al. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eat Weight Disord. 2016;21(3):353–64.

    Article  PubMed  PubMed Central  Google Scholar 

  3. van Hoeken D, Hoek HW. Review of the burden of eating disorders: mortality, disability, costs, quality of life, and family burden. Curr Opin Psychiatry. 2020;33(6):521–7.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Streatfeild J, Hickson J, Austin SB, Hutcheson R, Kandel JS, Lampert JG, et al. Social and economic cost of eating disorders in the United States: evidence to inform policy action. Int J Eat Disord. 2021;54(5):851–68.

    Article  PubMed  Google Scholar 

  5. Berkman ND, Bulik CM, Brownley KA, Lohr KN, Sedway JA, Rooks A, et al. Management of eating disorders. Evid Rep Technol Assess (Full Rep). 2006;135:1–166.

    Google Scholar 

  6. American Psychiatric Association. Practice guideline for the treatment of patients with eating disorders third edition. Am J Psychiatr. 2006;163:1–128.

  7. Fairburn CG. Eating disorders: the transdiagnostic view and the cognitive behavioral theory. Cognitive behavior therapy and eating disorders. New York, NY, US: Guilford Press; 2008. p. 7–22.

  8. Dalle Grave R, Calugi S, Conti M, Doll H, Fairburn CG. Inpatient cognitive behaviour therapy for anorexia nervosa: a randomized controlled trial. Psychother Psychosom. 2013;82(6):390–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Fairburn CG, Cooper Z, Doll HA, Norman P, O’Connor M. The natural course of bulimia nervosa and binge eating disorder in young women. Arch Gen Psychiatry. 2000;57(7):659–65.

    Article  CAS  PubMed  Google Scholar 

  10. Khalsa SS, Portnoff LC, McCurdy-McKinnon D, Feusner JD. What happens after treatment?. A systematic review of relapse, remission, and recovery in anorexia nervosa. J Eat Disord. 2017;5:20-.

  11. Richard M, Bauer S, Kordy H. Relapse in anorexia and bulimia nervosa a 2.5-year follow-up study. Eur Eat Disord Rev. 2005;13:180–90.

  12. Glasofer DR, Muratore AF, Attia E, Wu P, Wang Y, Minkoff H, et al. Predictors of illness course and health maintenance following inpatient treatment among patients with anorexia nervosa. J Eat Disord. 2020;8(1):69.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Davis H, Attia E. Pharmacotherapy of eating disorders. Curr Opin Psychiatry. 2017;30(6):452–7.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Golden NH, Attia E. Psychopharmacology of eating disorders in children and adolescents. Pediatr Clin North Am. 2011;58(1):121–38, xi.

  15. Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol. 2012;15(2):209–22.

    Article  CAS  PubMed  Google Scholar 

  16. Alañón Pardo MDM, Ferrit Martín M, Calleja Hernández M, Morillas MF. Adherence of psychopharmacological prescriptions to clinical practice guidelines in patients with eating behavior disorders. Eur J Clin Pharmacol. 2017;73(10):1305–13.

    Article  PubMed  Google Scholar 

  17. Garner DM, Anderson ML, Keiper CD, Whynott R, Parker L. Psychotropic medications in adult and adolescent eating disorders: clinical practice versus evidence-based recommendations. Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity. 2016;21(3):395–402.

    Article  Google Scholar 

  18. Mehler PS, Brown C. Anorexia nervosa – medical complications. J Eat Disord. 2015;3(1):11.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders. A meta-analysis of 36 studies. Arch Gen Psychiatry. 2011;68(7):724–31.

  20. Fichter MM, Quadflieg N. Mortality in eating disorders - results of a large prospective clinical longitudinal study. Int J Eat Disord. 2016;49(4):391–401.

    Article  PubMed  Google Scholar 

  21. Health NCCfM. Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. 2004.

  22. Wilson GT, Shafran R. Eating disorders guidelines from NICE. The Lancet. 2005;365(9453):79–81.

    Article  Google Scholar 

  23. Muratore AF, Attia E. Current therapeutic approaches to anorexia nervosa: state of the art. Clin Ther. 2021;43(1):85–94.

    Article  PubMed  Google Scholar 

  24. Bargiacchi A, Clarke J, Paulsen A, Leger J. Refeeding in anorexia nervosa. Eur J Pediatr. 2019;178(3):413–22.

    Article  PubMed  Google Scholar 

  25. Halmi KA, Eckert E, Marchi P, Sampugnaro V, Apple R, Cohen J. Comorbidity of psychiatric diagnoses in anorexia nervosa. Arch Gen Psychiatry. 1991;48(8):712–8.

    Article  CAS  PubMed  Google Scholar 

  26. Sidiropoulos M. Anorexia nervosa: the physiological consequences of starvation and the need for primary prevention efforts. Mcgill J Med. 2007;10(1):20–5.

    PubMed  PubMed Central  Google Scholar 

  27. Salbach-Andrae H, Lenz K, Simmendinger N, Klinkowski N, Lehmkuhl U, Pfeiffer E. Psychiatric comorbidities among female adolescents with anorexia nervosa. Child Psychiatry Hum Dev. 2008;39(3):261–72.

    Article  PubMed  Google Scholar 

  28. Kaye WH, Bulik CM, Thornton L, Barbarich N, Masters K. Comorbidity of anxiety disorders with anorexia and bulimia nervosa. Am J Psychiatry. 2004;161(12):2215–21.

    Article  PubMed  Google Scholar 

  29. Crow SJ. Pharmacologic treatment of eating disorders. Psychiatr Clin North Am. 2019;42(2):253–62.

    Article  PubMed  Google Scholar 

  30. Aigner M, Treasure J, Kaye W, Kasper S. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2011;12(6):400–43.

    Article  PubMed  Google Scholar 

  31. National Guideline A. National Institute for Health and Care Excellence: Clinical Guidelines. Eating disorders: recognition and treatment. London: National Institute for Health and Care Excellence (UK). Copyright © National Institute for Health and Care Excellence, 2017.

  32. Marvanova M, Gramith K. Role of antidepressants in the treatment of adults with anorexia nervosa. Ment Health Clin. 2018;8(3):127–37.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa?. Am J Psychiatry. 1998;155(4):548–51.

    Article  CAS  PubMed  Google Scholar 

  34. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006;295(22):2605–12.

    Article  CAS  PubMed  Google Scholar 

  35. Barbarich NC, McConaha CW, Halmi KA, Gendall K, Sunday SR, Gaskill J, et al. Use of nutritional supplements to increase the efficacy of fluoxetine in the treatment of anorexia nervosa. Int J Eat Disord. 2004;35(1):10–5.

    Article  PubMed  Google Scholar 

  36. Himmerich H, Kan C, Au K, Treasure J. Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. Pharmacol Ther. 2021;217: 107667.

    Article  CAS  PubMed  Google Scholar 

  37. McKnight RF, Park RJ. Atypical antipsychotics and anorexia nervosa: a review. Eur Eat Disord Rev. 2010;18(1):10–21.

    Article  PubMed  Google Scholar 

  38. •• Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. Am J Psychiatry. 2019;176(6):449-56. This manuscript details the findings of a RCT designed to evaluate the effects of 16-weeks of olanzapine versus placebo on changes in weight and psychological symptoms among adult outpatients with AN. Compared to patients receiving placebo (n = 77), individuals who received olanzapine (n = 75) demonstrated significantly greater increase in BMI over the course of treatment (mean BMI increase = 0.259; SD = 0.051). There were no group differences in rate of psychological symptom change.

  39. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry. 1984;144:288–92.

  40. Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand. 1982;66(6):445–50.

  41. Bissada H, Tasca GA, Barber AM, Bradwejn J. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2008;165(10):1281–8.

    Article  PubMed  Google Scholar 

  42. Dold M, Aigner M, Klabunde M, Treasure J, Kasper S. Second-generation antipsychotic drugs in anorexia nervosa: a meta-analysis of randomized controlled trials. Psychother Psychosom. 2015;84(2):110–6.

    Article  PubMed  Google Scholar 

  43. Attia E, Kaplan AS, Walsh BT, Gershkovich M, Yilmaz Z, Musante D, et al. Olanzapine versus placebo for out-patients with anorexia nervosa. Psychol Med. 2011;41(10):2177–82.

    Article  CAS  PubMed  Google Scholar 

  44. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006–11.

  45. Steinglass JE, Sysko R, Mayer L, Berner LA, Schebendach J, Wang Y, et al. Pre-meal anxiety and food intake in anorexia nervosa. Appetite. 2010;55(2):214–8.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Lavender JM, De Young KP, Wonderlich SA, Crosby RD, Engel SG, Mitchell JE, et al. Daily patterns of anxiety in anorexia nervosa: associations with eating disorder behaviors in the natural environment. J Abnorm Psychol. 2013;122(3):672–83.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lloyd EC, Powell C, Schebendach J, Walsh BT, Posner J, Steinglass JE. Associations between mealtime anxiety and food intake in anorexia nervosa. Int J Eat Disord. 2021;54(9):1711–6.

    Article  PubMed  Google Scholar 

  48. Steinglass JE, Kaplan SC, Liu Y, Wang Y, Walsh BT. The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: a preliminary report. Int J Eat Disord. 2014;47(8):901–4.

    Article  PubMed  Google Scholar 

  49. Renelli M, Fletcher J, Tupper KW, Files N, Loizaga-Velder A, Lafrance A. An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders. Eat Weight Disord. 2020;25(2):437–44.

    Article  PubMed  Google Scholar 

  50. • Spriggs MJ, Douglass HM, Park RJ, Read T, Danby JL, de Magalhães FJC, et al. Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study". Front Psychiatry. 2021;12:735523. This manuscript present a protocol for a pilot study designed to test the feasibility and effects of psilocybin as a treamtent for adult females with AN. The authors describe 1) ways in which they incorporated feedback from patients with lived experience) into the protocol and 2) the study protocol, which is designed to examine the effects of 3 oral doses of psilocybin over 6 weeks to 20 adult females with AN on behavioral (eating disorder psychopathology and readiness/motivation for recovery) and neuropsychological (changes in fMRI and EEG activity) outcomes.

  51. Westmoreland P, Krantz MJ, Mehler PS. Medical complications of anorexia nervosa and bulimia. Am J Med. 2016;129(1):30–7.

    Article  PubMed  Google Scholar 

  52. Gibson D, Workman C, Mehler PS. Medical complications of anorexia nervosa and bulimia nervosa. Psychiatr Clin North Am. 2019;42(2):263–74.

    Article  PubMed  Google Scholar 

  53. Chakraborty K, Basu D. Management of anorexia and bulimia nervosa: an evidence-based review. Indian J Psychiatry. 2010;52(2):174–86.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Bacaltchuk J, Hay PPJ. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database of Systematic Reviews. 2003(4).

  55. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord. 2007;40(4):321–36.

    Article  PubMed  Google Scholar 

  56. Pope HG, Hudson JI. Antidepressant drug therapy for bulimia: current status. J Clin Psychiatry. 1986;47(7):339–45.

    PubMed  Google Scholar 

  57. Israël M. Should some drugs be avoided when treating bulimia nervosa?. J Psychiatry Neurosci. 2002;27(6):457.

    PubMed Central  Google Scholar 

  58. Fluoxetine in the treatment of bulimia nervosa. a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry. 1992;49(2):139–47.

    Article  Google Scholar 

  59. Goldstein DJ, Wilson MG, Thompson VL, Potvin JH, Rampey AH, Jr. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry. 1995;166(5):660–6.

  60. Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry. 2002;159(1):96–102.

    Article  PubMed  Google Scholar 

  61. Kotler LA, Devlin MJ, Davies M, Walsh BT. An open trial of fluoxetine for adolescents with bulimia nervosa. J Child Adolesc Psychopharmacol. 2003;13(3):329–35.

    Article  PubMed  Google Scholar 

  62. •• Bello NT, Yeomans BL. Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder. Expert Opin Drug Saf. 2018;17(1):17-23. The authors gather information from RCTs, open label trials, and case reports and present a review of the safety and efficacy of FDA-approved medications fluoxetine and lisdexamfetamine for BN and BED, respectively. The review suggests both medications are effective, safe and well-tolerated among patients. Fluoxetine’s most common side effect is insomnia, whereas lisdexamfetamine is most commonly associated with headache, dry mouth, and insomnia. Lisdexamfetamine has a greater potential for abuse and long-term treatment can result in increases in heart rate and blood pressure. Despite the medications’ efficacy and safety, a subset of individuals do not respond to this treatment, suggesting need for additional behavioral and pharmacological treatments.

  63. Arbaizar B, Gómez-Acebo I, Llorca J. Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review. Gen Hosp Psychiatry. 2008;30(5):471–5.

    Article  PubMed  Google Scholar 

  64. Hedges DW, Reimherr FW, Hoopes SP, Rosenthal NR, Kamin M, Karim R, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64(12):1449–54.

    Article  CAS  PubMed  Google Scholar 

  65. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64(11):1335–41.

    Article  CAS  PubMed  Google Scholar 

  66. Nickel C, Tritt K, Muehlbacher M, Pedrosa Gil F, Mitterlehner FO, Kaplan P, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord. 2005;38(4):295–300.

    Article  PubMed  Google Scholar 

  67. Mitchell JE. Medical comorbidity and medical complications associated with binge-eating disorder. Int J Eat Disord. 2016;49(3):319–23.

    Article  PubMed  Google Scholar 

  68. Wassenaar E, Friedman J, Mehler PS. Medical complications of binge eating disorder. Psychiatr Clin North Am. 2019;42(2):275–86.

    Article  PubMed  Google Scholar 

  69. McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018;1411(1):96–105.

    Article  PubMed  Google Scholar 

  70. Amianto F, Ottone L, Abbate Daga G, Fassino S. Binge-eating disorder diagnosis and treatment: a recap in front of DSM-5. BMC Psychiatry. 2015;15:70-.

  71. McElroy SL. Pharmacologic treatments for binge-eating disorder. J Clin Psychiatry. 2017;78(Suppl 1):14–9.

    Article  PubMed  Google Scholar 

  72. Stefano SC, Bacaltchuk J, Blay SL, Appolinário JC. Antidepressants in short-term treatment of binge eating disorder: systematic review and meta-analysis. Eat Behav. 2008;9(2):129–36.

    Article  PubMed  Google Scholar 

  73. McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry. 2006;67(12):1897–906.

    Article  CAS  PubMed  Google Scholar 

  74. McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE. Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial. J Clin Psychiatry. 2004;65(1):50–6.

    Article  CAS  PubMed  Google Scholar 

  75. Ricca V, Castellini G, Lo Sauro C, Rotella CM, Faravelli C. Zonisamide combined with cognitive behavioral therapy in binge eating disorder: a one-year follow-up study. Psychiatry (Edgmont). 2009;6(11):23–8.

    Google Scholar 

  76. McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255–61.

    Article  PubMed  Google Scholar 

  77. McElroy SL, Shapira NA, Arnold LM, Keck PE, Rosenthal NR, Wu SC, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65(11):1463–9.

    Article  CAS  PubMed  Google Scholar 

  78. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039–48.

    Article  CAS  PubMed  Google Scholar 

  79. Himmerich H, Treasure J. Psychopharmacological advances in eating disorders. Expert Rev Clin Pharmacol. 2018;11(1):95–108.

    Article  CAS  PubMed  Google Scholar 

  80. McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2015;72(3):235–46.

    Article  Google Scholar 

  81. McElroy SL, Mitchell JE, Wilfley D, Gasior M, Ferreira-Cornwell MC, McKay M, et al. Lisdexamfetamine dimesylate effects on binge eating behaviour and obsessive-compulsive and impulsive features in adults with binge eating disorder. Eur Eat Disord Rev. 2016;24(3):223–31.

    Article  PubMed  Google Scholar 

  82. Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of lisdexamfetamine in adults with moderate to severe binge-eating disorder: a randomized clinical trial. JAMA Psychiat. 2017;74(9):903–10.

    Article  Google Scholar 

  83. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, et al. Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007;68(3):390–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Columbia University Irving Medical Center, 1051 Riverside Drive, Unit 98, New York, NY, USA

    Alexandra F. Muratore & Evelyn Attia

  2. Department of Psychiatry, New York State Psychiatric Institute, New York, NY, USA

    Alexandra F. Muratore & Evelyn Attia

  3. Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA

    Evelyn Attia

Authors
  1. Alexandra F. Muratore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evelyn Attia
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Drs. Muratore and Attia contributed to the research review, conceptualization, and writing of the manuscript.

Corresponding author

Correspondence to Alexandra F. Muratore.

Ethics declarations

Conflict of Interest

Dr. Attia serves as a clinical advisor to Equip Health, Inc., and receives royalties from UpToDate. The authors have no other competing interests to declare that are relevant to the content of this article.

Human and Animal Rights and Informed Consent

All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Eating Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Muratore, A.F., Attia, E. Psychopharmacologic Management of Eating Disorders. Curr Psychiatry Rep 24, 345–351 (2022). https://doi.org/10.1007/s11920-022-01340-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11920-022-01340-5

Keywords

Search

Navigation